Seres Therapeutics, Inc. Payments to Acquire Investments
Seres Therapeutics, Inc. (MCRB) reported Payments to Acquire Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-03-12
- Seres Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-12-31 was $0.00.
- Seres Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-09-30 was $0.00.
- Seres Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-06-30 was $0.00.
- Seres Therapeutics, Inc. payments to acquire investments for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $0.00.
- Seres Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Seres Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $4.43M, a 90.82% decline from fiscal 2022.
- Seres Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $48.22M, a 49.75% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month | Payments to Acquire Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $4.43M 10-K · filed 2026-03-12 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $4.43M 10-Q · filed 2024-11-13 | $16.51M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $4.43M 10-Q · filed 2024-08-13 | $16.51M derived: sum of 3 quarters · filed 2025-03-13 | $16.51M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | $4.43M 10-Q · filed 2024-05-08 | $16.51M derived: sum of 2 quarters · filed 2025-03-13 | $16.51M derived: sum of 3 quarters · filed 2025-03-13 | $24.49M derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | $12.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.08M derived: sum of 2 quarters · filed 2025-03-13 | $20.07M derived: sum of 3 quarters · filed 2025-03-13 | $48.22M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.98M derived: sum of 2 quarters · filed 2023-11-02 | $36.14M 10-Q · filed 2023-11-02 | $65.77M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $7.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $36.14M 10-Q · filed 2023-08-08 | $65.77M derived: sum of 3 quarters · filed 2024-03-05 | $80.17M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | $28.16M 10-Q · filed 2023-05-09 | $57.78M derived: sum of 2 quarters · filed 2024-03-05 | $72.19M derived: sum of 3 quarters · filed 2024-03-05 | $77.18M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | $29.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $44.03M derived: sum of 2 quarters · filed 2024-03-05 | $49.03M derived: sum of 3 quarters · filed 2024-03-05 | $95.97M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $14.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $19.40M derived: sum of 2 quarters · filed 2022-11-02 | $66.34M 10-Q · filed 2022-11-02 | $158.63M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2021-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $51.94M 10-Q · filed 2022-08-03 | $144.23M derived: sum of 3 quarters · filed 2023-03-07 | $257.30M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2021-03-31 | $46.94M 10-Q · filed 2022-05-04 | $139.23M derived: sum of 2 quarters · filed 2023-03-07 | $252.30M derived: sum of 3 quarters · filed 2023-03-07 | $252.30M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2020-12-31 | $92.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $205.35M derived: sum of 2 quarters · filed 2023-03-07 | $205.35M derived: sum of 3 quarters · filed 2023-03-07 | $218.28M 10-K · filed 2023-03-07 | |
| 2020-09-30 | $113.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $113.06M derived: sum of 2 quarters · filed 2021-11-10 | $126.00M 10-Q · filed 2021-11-10 | $138.01M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $12.93M 10-Q · filed 2021-08-03 | $24.94M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $12.93M 10-Q · filed 2021-05-04 | $24.94M derived: sum of 2 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $46.42M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $34.41M 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $6.38M derived: sum of 2 quarters · filed 2021-03-02 | $16.56M derived: sum of 3 quarters · filed 2021-03-02 | $21.83M 10-K · filed 2021-03-02 | |
| 2018-09-30 | $6.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $16.56M derived: sum of 2 quarters · filed 2019-11-05 | $21.83M 10-Q · filed 2019-11-05 | $44.04M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $10.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $15.46M 10-Q · filed 2019-08-06 | $37.66M derived: sum of 3 quarters · filed 2020-03-02 | $69.59M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $5.27M 10-Q · filed 2019-05-02 | $27.48M derived: sum of 2 quarters · filed 2020-03-02 | $59.41M derived: sum of 3 quarters · filed 2020-03-02 | $80.69M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2017-12-31 | $22.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $54.14M derived: sum of 2 quarters · filed 2020-03-02 | $75.42M derived: sum of 3 quarters · filed 2020-03-02 | $97.93M 10-K · filed 2020-03-02 | $96.53M 10-K · filed 2018-03-08 |
| 2017-09-30 | $31.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $53.22M derived: sum of 2 quarters · filed 2018-11-08 | $75.73M 10-Q · filed 2018-11-08 | $120.59M derived: sum of 4 quarters · filed 2019-03-06 | |
| 2017-06-30 | $21.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $43.80M 10-Q · filed 2018-08-02 | $88.66M derived: sum of 3 quarters · filed 2019-03-06 | $127.86M derived: sum of 4 quarters · filed 2019-03-06 | |
| 2017-03-31 | $22.51M 10-Q · filed 2018-05-09 | $67.38M derived: sum of 2 quarters · filed 2019-03-06 | $106.57M derived: sum of 3 quarters · filed 2019-03-06 | $267.81M derived: sum of 4 quarters · filed 2019-03-06 | |
| 2016-12-31 | $44.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $84.06M derived: sum of 2 quarters · filed 2019-03-06 | $245.29M derived: sum of 3 quarters · filed 2019-03-06 | $290.59M 10-K · filed 2019-03-06 | |
| 2016-09-30 | $39.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $200.43M derived: sum of 2 quarters · filed 2017-11-08 | $245.73M 10-Q · filed 2017-11-08 | $316.39M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | $161.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $206.53M 10-Q · filed 2017-08-03 | $277.19M derived: sum of 3 quarters · filed 2018-03-08 | $410.05M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-03-31 | $45.30M 10-Q · filed 2017-05-04 | $115.96M derived: sum of 2 quarters · filed 2018-03-08 | $248.81M derived: sum of 3 quarters · filed 2018-03-08 | $253.81M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2015-12-31 | $70.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $203.51M derived: sum of 2 quarters · filed 2018-03-08 | $208.51M derived: sum of 3 quarters · filed 2018-03-08 | $267.76M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $132.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $137.84M derived: sum of 2 quarters · filed 2016-11-10 | $197.10M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $64.25M 10-Q · filed 2016-08-11 | |||
| 2015-03-31 | $59.26M 10-Q · filed 2016-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |